<SEC-DOCUMENT>0001144204-17-018018.txt : 20170331
<SEC-HEADER>0001144204-17-018018.hdr.sgml : 20170331
<ACCEPTANCE-DATETIME>20170331124628
ACCESSION NUMBER:		0001144204-17-018018
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170331
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170331
DATE AS OF CHANGE:		20170331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		17729197

	BUSINESS ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219
		BUSINESS PHONE:		2149055100

	MAIL ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v463206_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 3pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT PURSUANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TO SECTION 13 OR 15(D) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of report (Date of earliest event reported):
<B>March 31, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>ABEONA THERAPEUTICS INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Delaware</U></B></FONT></TD>
    <TD STYLE="width: 34%; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>001-15771</U></B></FONT></TD>
    <TD STYLE="width: 33%; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>83-0221517</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>3333 Lee Parkway, Suite 600</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Dallas, TX 75219</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>(214)-665-9495</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>N/A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see<I>&nbsp;</I>General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2.02.&nbsp;&nbsp;&nbsp;Results of Operations and Financial
Condition. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2017, Abeona Therapeutics
Inc. issued a press release regarding its results of operations and financial condition for the quarter and year ended December
31, 2016. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in Item&nbsp;2.02 of this
Current Report on Form&nbsp;8-K and Exhibit&nbsp;99.1 attached hereto shall not be deemed &ldquo;filed&rdquo; for purposes of Section&nbsp;18
of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Financial Statements
and Exhibits. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="2" STYLE="text-decoration: underline"><FONT STYLE="font-size: 10pt"><B><U>Exhibit No.</U></B></FONT></TD>
    <TD STYLE="text-decoration: underline"><FONT STYLE="font-size: 10pt"><B><U>Description</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; width: 88%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">Press release dated March 31, 2017, entitled &ldquo;Abeona Therapeutics Inc. Reports Q4 2016 Financial Results and Business Highlights&rdquo;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-decoration: underline"><FONT STYLE="font-size: 10pt"><U>Abeona Therapeutics Inc.</U></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">(Registrant)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 51%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 46%; text-decoration: underline"><FONT STYLE="font-size: 10pt"><U>/s/ Stephen B. Thompson</U></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Stephen B. Thompson</FONT><BR>
<FONT STYLE="font-size: 10pt">Vice&nbsp;President&nbsp;Finance </FONT><BR>
<FONT STYLE="font-size: 10pt">Chief&nbsp;Accounting Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: March 31, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-decoration: underline"><FONT STYLE="font-size: 10pt"><U>Exhibit Number </U></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">Press release dated&nbsp;&nbsp;March 31, 2017, entitled &ldquo;Abeona Therapeutics Inc. Reports Q4 2016 Financial Results and Business Highlights&rdquo;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v463206_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 133px; width: 367px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Abeona Therapeutics Reports Q4 2016 Financial
<BR>
Results and Business Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><I>Management
to Host Investor Conference Call on Monday, April 10<SUP>th</SUP> at 10:00 am ET to <BR>
Provide Progress Report on Corporate Developments
</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NEW YORK, NY and CLEVELAND, OH</B> -
March 31, 2017 -- Abeona Therapeutics Inc. (NASDAQ: ABEO), a leading clinical-stage biopharmaceutical company focused on developing
novel gene therapies for life-threatening rare genetic diseases, today announced financial results for the fourth quarter. The
Company will host a call to update investors on recent clinical developments and year-end financial results on Monday, April 10<SUP>th</SUP>
at 10:00 am (Eastern). Interested parties are invited to participate in the call by dialing 877-269-7756 (toll free domestic) or
201-689-7817 (International).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;The past year has been characterized
by advancement across all clinical programs within Abeona, having achieved many important regulatory and clinical milestones in
2016. Notably, we initiated dosing of our high-dose cohort in ABO-102 this January after demonstrating promising safety and biopotency
in the completed low-dose cohort last year. The strength of our clinical programs was validated not only through critically reviewed
clinical data, but also through the achievement of multiple EMA and FDA designations for our gene therapy programs in 2016. Another
important highlight was the addition of our <FONT STYLE="background-color: white">AIM<SUP>TM </SUP>vector platform, which provides
Abeona the ability to leverage a proprietary AAV capsid portfolio for next generation gene therapies across multiple existing and
potential new indications,</FONT>&quot; stated Timothy J. Miller, Ph.D, President and CEO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Abeona Recent Highlights: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">On March 8, 2017, Abeona announced the European Medicines Agency (EMA) Committee for Orphan Medicinal
Products had granted Orphan Drug Designation for EB-101 in Epidermolysis Bullosa.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">On February 17, 2017, Abeona reported positive data from <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>the
leading clinical gene therapy program for Sanfilippo syndrome type A patients, ABO-102, demonstrating central nervous system (CNS)
and peripheral organ disease biopotency.</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify"><I>ABO-102 was well-tolerated in 4 subjects (N=3 low dose, N=1 high dose) through 650 days follow
up with no Serious Adverse Events </I></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify"><I>63% +/- 0.5% central nervous system reduction of heparan sulfate GAG 6 months post-injection
(N=2)</I></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify"><I>Continued evidence of biopotency: reduced liver and spleen volumes and decreased urinary GAGs</I></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify"><I>Two subjects assessed at the 6-month timepoint showed evidence for stabilization or improvement
(average 60% over 2 subjects) in several Mullen subdomains</I></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify"><I>Adaptive behavior ratings on the Vineland stabilized</I></TD></TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
                                                                                                                                                                                                                                   <TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">&nbsp;</TD><TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify"><I>Subjects showed improved ability to complete individual items on the Leiter-R non-verbal IQ
assessment resulting in improved raw scores</I></TD></TR></TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
                                                         <TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">&nbsp;</TD><TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">On February 1, 2017, Abeona enrolled the first high-dose subject in ABO-102 ongoing Phase 1/2 trial
in MPS III. ABO-102 received Fast Track Designation and has been granted Orphan Product Designation in the USA and Europe, and
has also received the Rare Pediatric Disease Designation in the United States. <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Global
ABO-102 enrollments in Europe and Australia are expected to commence later this year.</I></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">On January 19, 2017, the EMA Committee for Orphan Medicinal Products granted Orphan Drug Designation
(EMA/OD/226/16) for Abeona&rsquo;s gene therapy program ABO-101 for children impacted by Sanfilippo syndrome type B (MPS IIIB).
ABO-101 has previously been granted Orphan Product Designation in the United States and received the Rare Pediatric Disease Designation
as a pre-requisite part of the FDA&rsquo;s Priority Review Voucher (PRV) process.&nbsp; The FDA has allowed the Investigational
New Drug (IND) for a Phase 1/2 clinical trial, and enrollments are anticipated to begin later this year.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">On January 3, 2017, the EMA Committee for Orphan Medicinal Products granted Orphan Drug Designation
for Abeona's ABO-201 program (AAV-CLN3), the AAV-based single intravenous gene therapy program for juvenile Batten disease, a fatal
lysosomal storage disease of the nervous system caused by autosomal-recessive mutations in the <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>CLN3</I></FONT>
gene.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">On November 11, 2016, Abeona announced the publication of positive Phase 1 clinical results for
EB-101 in the Journal of the American Medical Association (JAMA). The paper highlighted that EB-101 therapy was well-tolerated
in patients with recessive dystrophic epidermolysis bullosa (RDEB), and the trial demonstrated clinical efficacy of 67% healed
wounds at 6 months post treatment, lasting through 12 months, including collage biomarker expression. The Company anticipates providing
a clinical update at the upcoming annual meeting of the Society for Investigative Dermatology, in April, 2017.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&quot;The fourth quarter of 2016 brought
significant progress in our goal of building a strong leadership position in the development of novel therapies for rare diseases,&quot;
stated Steven H. Rouhandeh, Executive Chairman. &quot;With the positive biopotency data seen in our ABO-102 Phase 1/2 clinical
trial in Sanfilippo syndrome Type A (MPS IIIA) and the continued enrollment of the high dose cohort, along with data seen in our
ongoing EB-101 Phase 2 study in epidermolysis bullosa, and the addition of our own proprietary vector platform, we remain focused
on furthering our regulatory and clinical progress as we continue our work for 2017.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4th Quarter and Year-end Summary Financial
Results:</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Cash position: Cash, cash equivalents and marketable securities as of December 31, 2016 were $69.1
million, compared to $31.2 million as of September 30, 2016. Net cash used in operating activities in the twelve months ended December
31, 2016 was $13 million as compared to $10.4 million in the same period in 2015, an increase of $2.6 million.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Offering: During the fourth quarter, on November 1, 2016, Abeona closed an underwritten public
offering of 6,000,000 shares of common stock, at a public offering price of $7.00 per share. The gross proceeds to the Company
were $42,000,000 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by
the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Revenues: Revenues were $256 thousand for the fourth quarter of 2016, compared to $215 thousand
in the fourth quarter of 2015. Revenues for twelve months ended December 31, 2016 were $889 thousand, compared to $1,040 thousand
in the same period in 2015. Revenues consisted of a combination of royalties from marketed products, primarily MuGard&reg;, and
recognition of deferred revenues related to upfront payments from early license agreements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Loss per share: Loss per share was $0.19 for the fourth quarter of 2016, compared to a loss per
share of $0.06 in the comparable period in 2015.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Abeona:</B> Abeona Therapeutics
Inc. is a leading clinical-stage biopharmaceutical company developing gene therapies for life-threatening rare genetic diseases.
Abeona's lead programs include ABO-102 (AAV-SGSH) and ABO-101 (AAV-NAGLU), adeno-associated virus (AAV) based gene therapies for
Sanfilippo syndrome (MPS IIIA and IIIB, respectively). Abeona is also developing EB-101 (gene-corrected skin grafts) for recessive
dystrophic epidermolysis bullosa (RDEB), EB-201 for epidermolysis bullosa (EB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten
disease (JNCL), ABO-202 (AAV-CLN1) gene therapy for treatment of infantile Batten disease (INCL), and ABO-301 (AAV-FANCC) for
Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood
diseases. In addition, Abeona has a plasma-based protein therapy pipeline, including SDF Alpha&trade; (alpha-1 protease inhibitor)
for inherited COPD, using its proprietary SDF&trade; (Salt Diafiltration) ethanol-free process. For more information, visit <U>www.abeonatherapeutics.com.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #26282A"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Investor Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Christine Silverstein</FONT><BR>
<FONT STYLE="background-color: white">Vice President, Investor Relations</FONT><BR>
Abeona Therapeutics Inc.<BR>
<FONT STYLE="background-color: white">+1 (212)-786-6212</FONT><BR>
<FONT STYLE="background-color: white">csilverstein@abeonatherapeutics.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Media Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Andre&rsquo;a Lucca<BR>
Vice President, Communications &amp; Operations<BR>
Abeona Therapeutics Inc.<BR>
+1 (212)-786-6208</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">alucca@abeonatherapeutics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This press release contains certain
statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve
risks and uncertainties. These statements are subject to numerous risks and uncertainties, including but not limited to continued
interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability
to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes
in the financial markets and global economic conditions; our belief that initial signals of biopotency and clinical activity, which
suggest that ABO-102 successfully reached target tissues throughout the body, including the central nervous system; our statement
that global ABO-102 enrollments in Europe and Australia are expected to commence later this year; our belief that the data demonstrate
an early and robust systemic delivery of ABO-102, and the increased reductions in CNS GAG support our approach for intravenous
delivery for subjects with Sanfilippo syndromes, and other risks as may be detailed from time to time in the Company's Annual Reports
on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations
to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances
occurring after the date of this release, whether as a result of new information, future developments or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "% 6\# 2(  A$! Q$!_\0
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M=P:9OD ,4EI#M.T]<\#VKFFKU5;YF$U>JK?,Z6BB@D#J<5T'0%%(2!U.,TM
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MH?&+1P/WFD:RA]/LX_\ BJ9-\6XYU,>D^&M7NK@C"*\.U<]LXR:](HI\]/\
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MTN[6<1"95N(PN],XR,$]^QP>>E9GAOQ&;S2])BNWDN-2NXVD<1H/D0,1O?&
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M6$SJD=Z\($1W-M4]=P4DC!(QR*OZCK4&G75O:>1<7-U<!F2"W0,VU<98Y(
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
